Insignificant disease among men with intermediate-risk prostate cancer

被引：0
|
作者：
Sung Kyu Hong
Emily Vertosick
Daniel D. Sjoberg
Peter T. Scardino
James A. Eastham
机构：
[1] Memorial Sloan-Kettering Cancer Center,Urology Service, Department of Surgery
[2] Seoul National University Bundang Hospital,Department of Urology
[3] Memorial Sloan-Kettering Cancer Center,Department of Epidemiology and Biostatistics
[4] Cornell University,Department of Urology, Weill Cornell Medical College
来源：
World Journal of Urology | 2014年 / 32卷
关键词：
Prostate; Prostatic neoplasms; Insignificant; Intermediate risk; Prediction;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：1417 / 1421
页数：4
相关论文
共 50 条
  • [1] Insignificant disease among men with intermediate-risk prostate cancer
    Hong, Sung Kyu
    Vertosick, Emily
    Sjoberg, Daniel D.
    Scardino, Peter T.
    Eastham, James A.
    WORLD JOURNAL OF UROLOGY, 2014, 32 (06) : 1417 - 1421
  • [2] Personalizing the Management of Men with Intermediate-risk Prostate Cancer
    D'Amico, Anthony V.
    EUROPEAN UROLOGY, 2013, 64 (06) : 903 - 904
  • [3] Androgen Deprivation Therapy and the Risk of Death From Prostate Cancer Among Men With Favorable or Unfavorable Intermediate-Risk Disease
    Keane, Florence K.
    Chen, Ming-Hui
    Zhang, Danjie
    Moran, Brian J.
    Braccioforte, Michelle H.
    D'Amico, Anthony V.
    CANCER, 2015, 121 (16) : 2713 - 2719
  • [4] Outcomes for Men with Intermediate-risk Prostate Cancer on Active Surveillance
    Courtney, P. T.
    Deka, R.
    Cherry, D. R.
    Nelson, T. J.
    Luterstein, E.
    Salans, M. A.
    Yip, A. T. T.
    Nalawade, V.
    Parsons, J. K.
    Kader, K.
    Stewart, T. F.
    Rose, B. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S121 - S122
  • [5] Trends in Active Surveillance for Men With Intermediate-Risk Prostate Cancer
    Diven, Marshall A.
    Tshering, Lhaden
    Ma, Xiaoyue
    Hu, Jim C.
    Barbieri, Christopher
    McClure, Timothy
    Nagar, Himanshu
    JAMA NETWORK OPEN, 2024, 7 (08)
  • [6] UTILITY OF ONCOTYPE DX IN MEN WITH INTERMEDIATE-RISK PROSTATE CANCER
    Cantu, Miguel
    Golan, Ron
    McCarthy, Hiral
    Scognamiglio, Theresa
    McClure, Timothy
    Barbieri, Christopher
    Robinson, Brian
    Khani, Francesca
    JOURNAL OF UROLOGY, 2018, 199 (04): : E207 - E207
  • [7] Outcomes of Active Surveillance for Men With Intermediate-Risk Prostate Cancer
    Cooperberg, Matthew R.
    Cowan, Janet E.
    Hilton, Joan F.
    Reese, Adam C.
    Zaid, Harras B.
    Porten, Sima P.
    Shinohara, Katsuto
    Meng, Maxwell V.
    Greene, Kirsten L.
    Carroll, Peter R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (02) : 228 - 234
  • [8] The Likelihood of Death From Prostate Cancer in Men With Favorable or Unfavorable Intermediate-Risk Disease
    Keane, Florence K.
    Chen, Ming-Hui
    Zhang, Danjie
    Loffredo, Marian J.
    Kantoff, Philip W.
    Renshaw, Andrew A.
    D'Amico, Anthony V.
    CANCER, 2014, 120 (12) : 1787 - 1793
  • [9] The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease
    Keane, Florence K.
    Chen, Ming-Hui
    Zhang, Danjie
    Loffredo, Marian J.
    Kantoff, Philip W.
    Renshaw, Andrew A.
    D'Amico, Anthony Victor
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [10] Prognostic Value of the Intermediate-risk Feature in Men with Favorable Intermediate-risk Prostate Cancer: Implications for Active Surveillance
    Sherer, Michael, V
    Leonard, Austin J.
    Nelson, Tyler J.
    Guram, Kripa
    De Moraes, Gustavo Rodrigues
    Javier-Desloges, Juan
    Kane, Christopher
    McKay, Rana R.
    Rose, Brent S.
    Bagrodia, Aditya
    EUROPEAN UROLOGY OPEN SCIENCE, 2023, 50 : 61 - 67
12345